Together with reports that human claudin-low cancer cell lines are significantly more sensitive to MEK inhibitors14, our findings may have important implications for the development of regimens to treat this triple-negative breast cancer subtype. The gene discussed is MAP2K7; the disease is triple-negative breast carcinoma.